Targeting the cancer genome

Bookmark and Share
Published: 13 Apr 2012
Views: 6636
Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

Dr Bill Sellers talks about his session at the AACR 2012 Annual Meeting on the five key issues on the genetic basis of cancer drug development.


Dr Sellers mentions previously successful drugs, such as gleevec, and how there needs to be a greater understanding of the cancer genome, which will lead to more therapies for diseases once thought to be unaffected by this type of treatment.